Experienced in Cutaneous Lupus Erythematosus (CLE)

Dr. Samuel Sanchez-Rivera

Dermatology
200 Grand Blvd Los Prados, 
Caguas, PR 
Experienced in Cutaneous Lupus Erythematosus (CLE)
200 Grand Blvd Los Prados, 
Caguas, PR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Samuel Sanchez-Rivera is a Dermatologist in Caguas, Puerto Rico. Dr. Sanchez-Rivera is rated as an Experienced provider by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). His top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Cutaneous Lupus Erythematosus (CLE).

His clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in PR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
First Medical Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mapfre Insurance
  • INSURANCE PLAN
  • MEDICARE MAPD
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MMM Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Plan De Salud Menonita
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

200 Grand Blvd Los Prados, Caguas, PR 00727

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

1 Total Publications

A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement.
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement.
Journal: Journal of the American Academy of Dermatology
Published: May 16, 2024
Similar Doctors
Experienced in Cutaneous Lupus Erythematosus (CLE)
Dr. Tania M. Gonzalez-Santiago
Dermatology
Experienced in Cutaneous Lupus Erythematosus (CLE)
Dr. Tania M. Gonzalez-Santiago
Dermatology

Laboratorio De Patologia Dr Noy

San Juan, PR 
 (14.2 miles away)
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Tania Gonzalez-Santiago is a Dermatologist in San Juan, Puerto Rico. Dr. Gonzalez-Santiago has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). Her top areas of expertise are Actinic Keratosis, Bowen's Disease, Psoriasis, and Melanoma.

Experienced in Cutaneous Lupus Erythematosus (CLE)
Dr. Luis J. Ortiz-Espinosa
Dermatology
Experienced in Cutaneous Lupus Erythematosus (CLE)
Dr. Luis J. Ortiz-Espinosa
Dermatology
Bayamon, PR 
 (14.9 miles away)
787-798-1993
Languages Spoken:
English
See accepted insurances

Luis Ortiz-Espinosa is a Dermatologist in Bayamon, Puerto Rico. Dr. Ortiz-Espinosa is rated as an Advanced provider by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). His top areas of expertise are Systemic Capillary Leak Syndrome, Telangiectasia, Spider Angioma, and Actinic Keratosis.

Experienced in Cutaneous Lupus Erythematosus (CLE)
Dr. Pedro J. Vendrell
Dermatology
Experienced in Cutaneous Lupus Erythematosus (CLE)
Dr. Pedro J. Vendrell
Dermatology
2431 Ave Las Americas, Suite 104 Porrata Pila, 
Ponce, PR 
 (38.3 miles away)
787-290-0121
Languages Spoken:
English
See accepted insurances

Pedro Vendrell is a Dermatologist in Ponce, Puerto Rico. Dr. Vendrell is rated as an Experienced provider by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). His top areas of expertise are Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE), Localized Scleroderma, and Cutaneous Lupus Erythematosus (CLE).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sanchez-Rivera's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile